Stockreport

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

Enanta Pharmaceuticals, Inc.  (ENTA) 
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.enanta.com/investor-overview
PDF Phase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy VolunteersTopline Data Expected in Q4 2026 WATERTOWN, Ma [Read more]